Social Determinants of Health and Symptom Burden During Cancer Treatment.
Name:
SDOHsymptomsFINAL_2024.pdf
Size:
406.3Kb
Format:
PDF
Description:
Final Accepted Manuscript
Author
Badger, Terry ASegrin, Chris
Crane, Tracy E
Chalasani, Pavani
Arslan, Waqas
Hadeed, Mary
Sikorskii, Alla
Affiliation
Community and Systems Health Science Division, Department of Psychiatry, Mel and Enid Zuckerman College of Public Health, The University of ArizonaCollege of Medicine, The University of Arizona, Phoenix
University of Arizona Cancer Center, University of Arizona
College of Nursing, The University of Arizona
Department of Communication, The University of Arizona
Issue Date
2022-12-09
Metadata
Show full item recordPublisher
Lippincott Williams and WilkinsCitation
Badger, Terry A.; Segrin, Chris; Crane, Tracy E.; Chalasani, Pavani; Arslan, Waqas; Hadeed, Mary; Sikorskii, Alla. Social Determinants of Health and Symptom Burden During Cancer Treatment. Nursing Research 72(2):p 103-113, 3/4 2023. | DOI: 10.1097/NNR.0000000000000636Journal
Nursing researchRights
© 2022 Wolters Kluwer Health, Inc. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background Cancer survivors (defined as individuals from diagnosis to the end of life) in treatment experience multiple physical and psychological symptoms (e.g., fatigue, pain, depression, anxiety, disturbed sleep) that influence their well-being and treatment outcomes. Underrepresented cancer survivors may disproportionately experience greater symptom burden (number of symptoms, symptom severity, depression, anxiety). Objectives The aim of this study was to examine the relationships of social determinants of health, including age, ethnicity, education, income and whether income meets the survivor's needs, neighborhood (rural vs. urban), access to healthcare (e.g., insurance), and social isolation, with symptom burden in cancer survivors. Methods This secondary analysis included baseline data from 400 cancer survivors of solid tumor cancers undergoing chemotherapy or targeted therapy who participated in a larger randomized trial of symptom management interventions. Symptom burden was measured by the Center for Epidemiological Studies-Depression scale for depression and Patient-Reported Outcomes Measurement Information System scores for anxiety and social isolation, summed severity index of 16 symptoms from the General Symptom Distress Scale, and the total number of symptoms. Self-reported comorbid conditions were measured using the Bayliss tool. General linear models were used to relate symptom measures (one at a time) to age, number of comorbid conditions, level of education, marital status, income meeting needs, and size of metropolitan neighborhood. Additional covariates included site of cancer, its treatment, and whether the cancer was metastatic. Results Non-Hispanic White survivors (n = 191) were older and had more comorbid conditions, a higher proportion of metastatic cancers, and higher levels of education and income compared with Hispanic survivors (n = 168) and non-Hispanic survivors of other races (n = 41). Compared with the other two groups, Hispanic survivors had the lowest rate of health insurance availability, and non-Hispanic survivors of other races had the lowest social isolation. Age, number of comorbid conditions, and social isolation were significantly associated with number of symptoms, symptom severity, and depression. Age and social isolation were associated with anxiety. In addition, the symptom severity of non-Hispanic White survivors was lower than that of Hispanic survivors and non-Hispanic survivors of other races. Discussion These findings highlight the health disparities in symptom burden experienced among cancer survivors when considering their social determinants of health. Assessing these may help clinicians address health disparities in cancer care. CopyrightNote
12 month embargo; first published 09 December 2022EISSN
1538-9847PubMed ID
36729777Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1097/NNR.0000000000000636